Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

EPIKOL, a chromatin-focused CRISPR/Cas9-based screening platform to identify cancer-specific epigenetic vulnerabilities

ABSTRACT: EPIKOL, a chromatin-focused CRISPR/Cas9-based screening platform to identify cancer-specific epigenetic vulnerabilities

PROVIDER: PRJNA727487 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR14428500_1.fastq.gz	Fastqsanger.gz
	SRR14428500_2.fastq.gz	Fastqsanger.gz
	SRR14428501_1.fastq.gz	Fastqsanger.gz
	SRR14428501_2.fastq.gz	Fastqsanger.gz
	SRR14428502_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 127

Similar Datasets

EPIKOL, a chromatin-focused CRISPR/Cas9-based screening platform to identify cancer-specific epigenetic vulnerabilities

Project description:Dysregulation of the epigenome due to alterations in chromatin modifier proteins commonly contribute to malignant transformation. To interrogate the roles of epigenetic modifiers in cancer cells, we generated an epigenome-wide CRISPR-Cas9 knockout library (EPIKOL) that targets a wide-range of epigenetic modifiers and their cofactors. We conducted eight screens in two different cancer types and showed that EPIKOL performs with high efficiency in terms of sgRNA distribution and depletion of essential genes. We discovered novel epigenetic modifiers that regulate triple-negative breast cancer and prostate cancer cell fitness. We confirmed the growth-regulatory functions of individual candidates, including SS18L2 and members of the NSL complex (KANSL2, KANSL3, KAT8) in triple negative breast cancer cells. Overall, we show that EPIKOL, a focused sgRNA library targeting approximately 800 genes, can reveal epigenetic modifiers that are essential for cancer cell fitness under in vitro and in vivo conditions and enable identification of novel anti-cancer targets. Due to its comprehensive epigenome-wide targets and relatively high number of sgRNAs per gene, EPIKOL will facilitate studies examining functional roles of epigenetic modifiers in a wide range of contexts, such as screens in primary cells, patient-derived xenografts as well as in vivo models.

2022-08-24 | GSE173892 | GEO

EPIKOL, a chromatin-focused CRISPR/Cas9-based screening platform, to identify cancer-specific epigenetic vulnerabilities.

Project description:Dysregulation of the epigenome due to alterations in chromatin modifier proteins commonly contribute to malignant transformation. To interrogate the roles of epigenetic modifiers in cancer cells, we generated an epigenome-wide CRISPR-Cas9 knockout library (EPIKOL) that targets a wide-range of epigenetic modifiers and their cofactors. We conducted eight screens in two different cancer types and showed that EPIKOL performs with high efficiency in terms of sgRNA distribution and depletion of essential genes. We discovered novel epigenetic modifiers that regulate triple-negative breast cancer (TNBC) and prostate cancer cell fitness. We confirmed the growth-regulatory functions of individual candidates, including SS18L2 and members of the NSL complex (KANSL2, KANSL3, KAT8) in TNBC cells. Overall, we show that EPIKOL, a focused sgRNA library targeting ~800 genes, can reveal epigenetic modifiers that are essential for cancer cell fitness under in vitro and in vivo conditions and enable the identification of novel anti-cancer targets. Due to its comprehensive epigenome-wide targets and relatively high number of sgRNAs per gene, EPIKOL will facilitate studies examining functional roles of epigenetic modifiers in a wide range of contexts, such as screens in primary cells, patient-derived xenografts as well as in vivo models.

| S-EPMC9381743 | biostudies-literature

Establishing murine trophoblast organoids as a platform for CRISPR-Cas9 screening

Project description:Establishing murine trophoblast organoids as a platform for CRISPR-Cas9 screening

| PRJNA1027430 | ENA

Establishing murine trophoblast organoids as a platform for CRISPR-Cas9 screening [sgRNA]

Project description:Establishing murine trophoblast organoids as a platform for CRISPR-Cas9 screening [sgRNA]

| PRJNA1027380 | ENA

Establishing murine trophoblast organoids as a platform for CRISPR-Cas9 screening [scRNA-seq]

Project description:Establishing murine trophoblast organoids as a platform for CRISPR-Cas9 screening [scRNA-seq]

| PRJNA934269 | ENA

Genopal: a novel platform for focused microarray analysis

Project description:This SuperSeries is composed of the following subset Series: GSE16945: Comparative transcription profiling of peripheral blood mononuclear cells from vasculitis patients GSE18247: Focused transcription profiling of peripheral blood mononuclear cells from vasculitis patients Refer to individual Series

2010-11-10 | E-GEOD-18316 | biostudies-arrayexpress

Ex-vivo screening platform to identify tumor-specific therapies

Project description:Ex-vivo screening platform to identify tumor-specific therapies

| PRJNA417676 | ENA

Microbe-focused glycan array screening platform.

Project description:Interactions between glycans and glycan binding proteins are essential for numerous processes in all kingdoms of life. Glycan microarrays are an excellent tool to examine protein-glycan interactions. Here, we present a microbe-focused glycan microarray platform based on oligosaccharides obtained by chemical synthesis. Glycans were generated by combining different carbohydrate synthesis approaches including automated glycan assembly, solution-phase synthesis, and chemoenzymatic methods. The current library of more than 300 glycans is as diverse as the mammalian glycan array from the Consortium for Functional Glycomics and, due to its microbial focus, highly complementary. This glycan platform is essential for the characterization of various classes of glycan binding proteins. Applications of this glycan array platform are highlighted by the characterization of innate immune receptors and bacterial virulence factors as well as the analysis of human humoral immunity to pathogenic glycans.

| S-EPMC6369816 | biostudies-literature

Epigenetic-focused CRISPR/Cas9 screen identifies ASH2L as a regulator of glioblastoma cell survival

Project description:Epigenetic-focused CRISPR/Cas9 screen identifies ASH2L as a regulator of glioblastoma cell survival

| PRJNA832577 | ENA

CRISPR/Cas9 and cDNA overexpression screens to identify transmembrane transporters involved in PROTAC sensitivity/resistance

Project description:Proteolysis targeting chimeras (PROTACs) are bifunctional molecules that induce selective protein degradation by linking an E3 ubiquitin ligase enzyme to a target protein. Here we used transporter-focused and genome-wide CRISPR/Cas9 as well as a barcoded solute carriere (SLC)-focused cDNA libraray to screen for transporters that are involved in the resistance or sensitivity to BET- and SLC9-targeting PROTACs.

2024-09-23 | GSE272433 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data